Shmuel Yaccoby
Concepts (353)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Multiple Myeloma | 70 | 2023 | 3024 | 5.650 |
Why?
| Osteoclasts | 17 | 2015 | 472 | 2.740 |
Why?
| Bone Diseases | 7 | 2014 | 108 | 2.440 |
Why?
| Gene Expression Regulation, Neoplastic | 14 | 2018 | 867 | 1.840 |
Why?
| Osteoblasts | 13 | 2012 | 526 | 1.550 |
Why?
| Neoplasm Proteins | 7 | 2018 | 367 | 1.380 |
Why?
| Osteolysis | 6 | 2013 | 88 | 1.340 |
Why?
| Boronic Acids | 13 | 2013 | 197 | 1.320 |
Why?
| Coculture Techniques | 12 | 2015 | 158 | 1.280 |
Why?
| Mice, SCID | 21 | 2015 | 196 | 1.280 |
Why?
| Bone Marrow | 10 | 2018 | 415 | 1.150 |
Why?
| Bone Neoplasms | 3 | 2014 | 191 | 1.070 |
Why?
| Cell Differentiation | 14 | 2018 | 717 | 1.020 |
Why?
| Bone and Bones | 9 | 2014 | 523 | 1.000 |
Why?
| Pyrazines | 12 | 2013 | 203 | 1.000 |
Why?
| Proteoglycans | 6 | 2008 | 97 | 0.950 |
Why?
| Protein-Tyrosine Kinases | 2 | 2014 | 100 | 0.920 |
Why?
| Bone Marrow Cells | 5 | 2015 | 234 | 0.890 |
Why?
| Mice | 30 | 2015 | 6436 | 0.880 |
Why?
| Cell Proliferation | 11 | 2023 | 1099 | 0.850 |
Why?
| Cell Communication | 3 | 2015 | 70 | 0.820 |
Why?
| Neoplastic Stem Cells | 2 | 2017 | 103 | 0.810 |
Why?
| Osteogenesis | 5 | 2012 | 381 | 0.730 |
Why?
| Membrane Glycoproteins | 8 | 2009 | 269 | 0.730 |
Why?
| Bone Resorption | 4 | 2011 | 326 | 0.710 |
Why?
| Cell Movement | 6 | 2014 | 276 | 0.710 |
Why?
| Intercellular Signaling Peptides and Proteins | 3 | 2010 | 123 | 0.700 |
Why?
| Adipocytes | 2 | 2018 | 132 | 0.690 |
Why?
| Animals | 33 | 2016 | 14435 | 0.690 |
Why?
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2018 | 11 | 0.680 |
Why?
| Antineoplastic Agents | 10 | 2015 | 1295 | 0.630 |
Why?
| Humans | 70 | 2023 | 54132 | 0.630 |
Why?
| Gene Expression | 3 | 2018 | 667 | 0.610 |
Why?
| Gene Expression Regulation, Enzymologic | 2 | 2017 | 209 | 0.580 |
Why?
| Gene Expression Profiling | 9 | 2023 | 1138 | 0.580 |
Why?
| Tumor Microenvironment | 2 | 2015 | 207 | 0.570 |
Why?
| Protease Inhibitors | 4 | 2010 | 64 | 0.570 |
Why?
| Cell Survival | 9 | 2015 | 661 | 0.560 |
Why?
| Plasma Cells | 8 | 2012 | 238 | 0.540 |
Why?
| Cytokines | 3 | 2015 | 678 | 0.520 |
Why?
| Cysteine-Rich Protein 61 | 1 | 2014 | 4 | 0.510 |
Why?
| Disease Models, Animal | 8 | 2016 | 1645 | 0.500 |
Why?
| Nicotinamide Phosphoribosyltransferase | 1 | 2013 | 6 | 0.460 |
Why?
| Mesenchymal Stem Cell Transplantation | 1 | 2012 | 19 | 0.430 |
Why?
| Cell Line, Tumor | 10 | 2015 | 1542 | 0.430 |
Why?
| Rabbits | 6 | 2013 | 440 | 0.420 |
Why?
| Wnt Proteins | 2 | 2010 | 110 | 0.400 |
Why?
| Up-Regulation | 3 | 2013 | 514 | 0.400 |
Why?
| Angiogenesis Inhibitors | 2 | 2010 | 203 | 0.390 |
Why?
| Parathyroid Hormone | 4 | 2010 | 215 | 0.390 |
Why?
| Thalidomide | 7 | 2016 | 398 | 0.380 |
Why?
| Signal Transduction | 6 | 2013 | 1754 | 0.360 |
Why?
| Receptor, EphB4 | 1 | 2009 | 5 | 0.360 |
Why?
| Ephrin-B2 | 1 | 2009 | 6 | 0.360 |
Why?
| Fenretinide | 1 | 2009 | 5 | 0.360 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2016 | 1061 | 0.350 |
Why?
| Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2009 | 8 | 0.350 |
Why?
| Placenta | 1 | 2011 | 135 | 0.350 |
Why?
| Dipeptides | 1 | 2009 | 20 | 0.350 |
Why?
| Cell Adhesion Molecules | 1 | 2009 | 87 | 0.340 |
Why?
| Disease Progression | 8 | 2014 | 915 | 0.340 |
Why?
| Models, Biological | 4 | 2010 | 824 | 0.340 |
Why?
| Bone Development | 1 | 2009 | 69 | 0.330 |
Why?
| Tumor Necrosis Factor Ligand Superfamily Member 13 | 1 | 2007 | 3 | 0.320 |
Why?
| Transmembrane Activator and CAML Interactor Protein | 1 | 2007 | 3 | 0.320 |
Why?
| Extracellular Matrix Proteins | 1 | 2008 | 75 | 0.320 |
Why?
| Recombinant Fusion Proteins | 1 | 2007 | 206 | 0.300 |
Why?
| Apoptosis | 8 | 2012 | 1306 | 0.300 |
Why?
| Bone Remodeling | 4 | 2012 | 180 | 0.300 |
Why?
| Melphalan | 3 | 2016 | 181 | 0.290 |
Why?
| Prognosis | 12 | 2018 | 2116 | 0.290 |
Why?
| Tumor Cells, Cultured | 8 | 2013 | 483 | 0.290 |
Why?
| Neoplasm Recurrence, Local | 3 | 2023 | 643 | 0.280 |
Why?
| Antibodies | 1 | 2006 | 177 | 0.280 |
Why?
| Immunohistochemistry | 5 | 2015 | 1097 | 0.280 |
Why?
| Serine Endopeptidases | 1 | 2006 | 57 | 0.270 |
Why?
| RNA, Small Interfering | 4 | 2013 | 254 | 0.270 |
Why?
| Antigens, Neoplasm | 1 | 2006 | 170 | 0.260 |
Why?
| Severe Combined Immunodeficiency | 1 | 2005 | 12 | 0.260 |
Why?
| Transplantation, Heterologous | 5 | 2009 | 76 | 0.260 |
Why?
| Alkaline Phosphatase | 6 | 2017 | 101 | 0.250 |
Why?
| Syndecan-1 | 6 | 2007 | 82 | 0.250 |
Why?
| NF-kappa B | 4 | 2013 | 336 | 0.240 |
Why?
| Receptors, CXCR4 | 2 | 2014 | 31 | 0.240 |
Why?
| Hematopoietic Stem Cells | 3 | 2012 | 215 | 0.240 |
Why?
| Gene Knockdown Techniques | 2 | 2014 | 127 | 0.230 |
Why?
| Flow Cytometry | 6 | 2015 | 548 | 0.230 |
Why?
| Bone Density | 3 | 2010 | 417 | 0.230 |
Why?
| Killer Cells, Natural | 2 | 2015 | 107 | 0.220 |
Why?
| Positron-Emission Tomography | 2 | 2017 | 323 | 0.220 |
Why?
| Translocation, Genetic | 2 | 2021 | 286 | 0.220 |
Why?
| Stromal Cells | 1 | 2003 | 80 | 0.220 |
Why?
| Immunotherapy, Adoptive | 2 | 2015 | 130 | 0.220 |
Why?
| Transcription Factors | 2 | 2023 | 619 | 0.210 |
Why?
| Neoplasm Transplantation | 3 | 2014 | 94 | 0.210 |
Why?
| Immunophenotyping | 2 | 2015 | 117 | 0.210 |
Why?
| Female | 21 | 2018 | 28437 | 0.210 |
Why?
| Neovascularization, Pathologic | 3 | 2009 | 172 | 0.210 |
Why?
| Epigenomics | 1 | 2021 | 67 | 0.200 |
Why?
| Immunoglobulin Light Chains | 2 | 2015 | 100 | 0.200 |
Why?
| T-Lymphocytes | 2 | 2015 | 370 | 0.200 |
Why?
| Cell Line | 2 | 2015 | 1166 | 0.200 |
Why?
| Decorin | 2 | 2012 | 6 | 0.190 |
Why?
| Antibodies, Monoclonal | 4 | 2016 | 560 | 0.180 |
Why?
| Oligonucleotide Array Sequence Analysis | 4 | 2015 | 473 | 0.180 |
Why?
| Drug Resistance, Neoplasm | 2 | 2015 | 309 | 0.180 |
Why?
| Syndecans | 5 | 2006 | 43 | 0.180 |
Why?
| Neoplasm Metastasis | 2 | 2014 | 252 | 0.180 |
Why?
| Cells, Cultured | 4 | 2013 | 1755 | 0.170 |
Why?
| Genes, myc | 1 | 2019 | 47 | 0.170 |
Why?
| Cell Division | 4 | 2004 | 330 | 0.170 |
Why?
| Cell Adhesion | 2 | 2014 | 171 | 0.170 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2015 | 682 | 0.160 |
Why?
| Cyclin-Dependent Kinases | 2 | 2015 | 35 | 0.160 |
Why?
| Male | 17 | 2018 | 27350 | 0.160 |
Why?
| Mice, Transgenic | 4 | 2007 | 662 | 0.160 |
Why?
| Risk Factors | 5 | 2018 | 3936 | 0.150 |
Why?
| Hexokinase | 1 | 2017 | 15 | 0.150 |
Why?
| Diffusion Magnetic Resonance Imaging | 1 | 2018 | 127 | 0.150 |
Why?
| Monoclonal Gammopathy of Undetermined Significance | 2 | 2018 | 108 | 0.150 |
Why?
| Chromosomes, Human, Pair 17 | 1 | 2017 | 43 | 0.150 |
Why?
| Calcification, Physiologic | 1 | 2017 | 41 | 0.150 |
Why?
| Tumor Suppressor Protein p53 | 2 | 2017 | 251 | 0.150 |
Why?
| Disease-Free Survival | 5 | 2018 | 488 | 0.150 |
Why?
| Chromosome Aberrations | 3 | 2016 | 315 | 0.150 |
Why?
| Proteasome Inhibitors | 2 | 2016 | 110 | 0.150 |
Why?
| Pelvis | 1 | 2017 | 75 | 0.150 |
Why?
| Chromosome Deletion | 1 | 2017 | 151 | 0.140 |
Why?
| Stem Cells | 2 | 2009 | 192 | 0.140 |
Why?
| Neoplasm, Residual | 1 | 2017 | 167 | 0.140 |
Why?
| Pyridinium Compounds | 1 | 2015 | 18 | 0.140 |
Why?
| Neoplasms, Experimental | 2 | 2007 | 115 | 0.140 |
Why?
| Recurrence | 3 | 2014 | 692 | 0.140 |
Why?
| Biopsy | 2 | 2018 | 694 | 0.140 |
Why?
| Fluorodeoxyglucose F18 | 1 | 2017 | 205 | 0.140 |
Why?
| Base Sequence | 2 | 2008 | 732 | 0.140 |
Why?
| Homologous Recombination | 1 | 2015 | 43 | 0.140 |
Why?
| Xenograft Model Antitumor Assays | 3 | 2015 | 219 | 0.130 |
Why?
| Benzimidazoles | 1 | 2015 | 54 | 0.130 |
Why?
| Peptide Nucleic Acids | 1 | 2015 | 16 | 0.130 |
Why?
| Rad51 Recombinase | 1 | 2015 | 21 | 0.130 |
Why?
| Endothelial Cells | 2 | 2009 | 296 | 0.130 |
Why?
| Genes, Neoplasm | 1 | 2015 | 36 | 0.130 |
Why?
| Bromodeoxyuridine | 2 | 2005 | 21 | 0.130 |
Why?
| Aged | 11 | 2017 | 10059 | 0.130 |
Why?
| Immunologic Factors | 1 | 2016 | 130 | 0.130 |
Why?
| Genomic Instability | 1 | 2015 | 95 | 0.130 |
Why?
| Asymptomatic Diseases | 1 | 2014 | 43 | 0.120 |
Why?
| Antigens, CD | 1 | 2015 | 242 | 0.120 |
Why?
| Carrier Proteins | 4 | 2008 | 360 | 0.120 |
Why?
| Time Factors | 7 | 2017 | 3223 | 0.120 |
Why?
| Proteome | 1 | 2015 | 176 | 0.120 |
Why?
| Immunotherapy | 1 | 2016 | 260 | 0.120 |
Why?
| Nicotinamide Mononucleotide | 1 | 2013 | 4 | 0.120 |
Why?
| Acrylamides | 1 | 2013 | 8 | 0.120 |
Why?
| Antigens, CD19 | 2 | 2005 | 19 | 0.120 |
Why?
| Chemokine CXCL12 | 1 | 2013 | 31 | 0.110 |
Why?
| Interleukin-6 | 2 | 2005 | 315 | 0.110 |
Why?
| NAD | 1 | 2013 | 46 | 0.110 |
Why?
| Niacinamide | 1 | 2013 | 25 | 0.110 |
Why?
| Poly(ADP-ribose) Polymerases | 1 | 2013 | 43 | 0.110 |
Why?
| Enzyme Induction | 1 | 2013 | 80 | 0.110 |
Why?
| Sirtuin 1 | 1 | 2013 | 29 | 0.110 |
Why?
| Amides | 1 | 2013 | 44 | 0.110 |
Why?
| beta Catenin | 1 | 2013 | 102 | 0.110 |
Why?
| Oligopeptides | 1 | 2013 | 95 | 0.110 |
Why?
| Tumor Burden | 2 | 2010 | 142 | 0.110 |
Why?
| Nitriles | 1 | 2013 | 71 | 0.110 |
Why?
| Leukemia | 1 | 2013 | 70 | 0.110 |
Why?
| Myelodysplastic Syndromes | 1 | 2013 | 79 | 0.110 |
Why?
| Proteomics | 1 | 2015 | 341 | 0.110 |
Why?
| Middle Aged | 11 | 2018 | 13094 | 0.110 |
Why?
| Piperidines | 1 | 2013 | 102 | 0.110 |
Why?
| Magnetic Resonance Imaging | 2 | 2012 | 1603 | 0.110 |
Why?
| Injections, Intravenous | 1 | 2012 | 148 | 0.110 |
Why?
| Enzyme Inhibitors | 2 | 2013 | 456 | 0.110 |
Why?
| Proto-Oncogene Proteins c-jun | 2 | 2009 | 83 | 0.110 |
Why?
| Myeloma Proteins | 2 | 2004 | 26 | 0.110 |
Why?
| Cytotoxicity, Immunologic | 1 | 2012 | 62 | 0.110 |
Why?
| Remission Induction | 1 | 2012 | 222 | 0.110 |
Why?
| Neoplasm Staging | 3 | 2015 | 801 | 0.100 |
Why?
| RNA, Messenger | 3 | 2015 | 1222 | 0.100 |
Why?
| Anti-Inflammatory Agents | 1 | 2012 | 177 | 0.100 |
Why?
| Renal Insufficiency | 1 | 2012 | 138 | 0.100 |
Why?
| Glycoproteins | 2 | 2001 | 132 | 0.100 |
Why?
| beta 2-Microglobulin | 2 | 2007 | 35 | 0.090 |
Why?
| Lymph Nodes | 1 | 2012 | 282 | 0.090 |
Why?
| JNK Mitogen-Activated Protein Kinases | 2 | 2007 | 78 | 0.090 |
Why?
| Early Growth Response Protein 1 | 1 | 2009 | 42 | 0.090 |
Why?
| Sphingosine | 1 | 2009 | 27 | 0.090 |
Why?
| Myocardium | 1 | 2012 | 445 | 0.090 |
Why?
| Lysophospholipids | 1 | 2009 | 34 | 0.090 |
Why?
| Dexamethasone | 3 | 2007 | 448 | 0.090 |
Why?
| Bone Transplantation | 2 | 2010 | 55 | 0.090 |
Why?
| Organoids | 1 | 2009 | 41 | 0.090 |
Why?
| Drug Screening Assays, Antitumor | 1 | 2009 | 142 | 0.080 |
Why?
| p38 Mitogen-Activated Protein Kinases | 1 | 2009 | 99 | 0.080 |
Why?
| Leukocytes, Mononuclear | 1 | 2009 | 133 | 0.080 |
Why?
| Caspases | 1 | 2009 | 147 | 0.080 |
Why?
| Glucuronidase | 2 | 2007 | 48 | 0.080 |
Why?
| Enzyme Activation | 1 | 2009 | 333 | 0.080 |
Why?
| Wnt3 Protein | 1 | 2008 | 8 | 0.080 |
Why?
| Lentivirus | 1 | 2008 | 18 | 0.080 |
Why?
| Prospective Studies | 5 | 2016 | 2607 | 0.080 |
Why?
| Wnt3A Protein | 1 | 2008 | 13 | 0.080 |
Why?
| Ellipticines | 1 | 2008 | 6 | 0.080 |
Why?
| B-Cell Activating Factor | 1 | 2007 | 3 | 0.080 |
Why?
| Bone Density Conservation Agents | 1 | 2009 | 81 | 0.080 |
Why?
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2008 | 96 | 0.080 |
Why?
| Cytological Techniques | 1 | 2007 | 14 | 0.080 |
Why?
| Diploidy | 1 | 2007 | 30 | 0.080 |
Why?
| Precancerous Conditions | 1 | 2008 | 93 | 0.080 |
Why?
| Genetic Vectors | 1 | 2008 | 136 | 0.080 |
Why?
| Karyotyping | 1 | 2007 | 93 | 0.080 |
Why?
| RNA Interference | 1 | 2008 | 195 | 0.080 |
Why?
| Heparan Sulfate Proteoglycans | 1 | 2007 | 14 | 0.080 |
Why?
| Diphosphonates | 1 | 2008 | 94 | 0.080 |
Why?
| Hematopoietic Stem Cell Transplantation | 1 | 2012 | 570 | 0.080 |
Why?
| Phosphorylation | 1 | 2009 | 609 | 0.080 |
Why?
| Receptor Activator of Nuclear Factor-kappa B | 2 | 2004 | 32 | 0.080 |
Why?
| Models, Animal | 1 | 2007 | 255 | 0.070 |
Why?
| Reactive Oxygen Species | 1 | 2009 | 494 | 0.070 |
Why?
| Mice, Inbred C57BL | 1 | 2012 | 2021 | 0.070 |
Why?
| Phenotype | 2 | 2009 | 822 | 0.070 |
Why?
| Immunosuppressive Agents | 1 | 2008 | 249 | 0.070 |
Why?
| Kidney | 1 | 2012 | 828 | 0.070 |
Why?
| Gelatinases | 1 | 2006 | 36 | 0.070 |
Why?
| Treatment Outcome | 6 | 2017 | 5596 | 0.070 |
Why?
| Endopeptidases | 1 | 2006 | 75 | 0.070 |
Why?
| Risk Assessment | 3 | 2018 | 1363 | 0.070 |
Why?
| Antigens, CD34 | 1 | 2005 | 80 | 0.070 |
Why?
| Survival Analysis | 2 | 2018 | 739 | 0.070 |
Why?
| RANK Ligand | 2 | 2004 | 183 | 0.070 |
Why?
| Adult | 6 | 2018 | 14196 | 0.070 |
Why?
| Fetal Tissue Transplantation | 1 | 2005 | 7 | 0.070 |
Why?
| Hematologic Neoplasms | 1 | 2006 | 99 | 0.060 |
Why?
| Metaphase | 2 | 2016 | 54 | 0.060 |
Why?
| Annexin A5 | 1 | 2004 | 14 | 0.060 |
Why?
| Culture Media, Conditioned | 1 | 2004 | 52 | 0.060 |
Why?
| Phagocytosis | 1 | 2004 | 51 | 0.060 |
Why?
| Molecular Sequence Data | 1 | 2006 | 996 | 0.060 |
Why?
| Endothelium, Vascular | 1 | 2006 | 293 | 0.060 |
Why?
| Survival Rate | 2 | 2018 | 955 | 0.060 |
Why?
| Clinical Trials as Topic | 3 | 2016 | 489 | 0.060 |
Why?
| Membrane Proteins | 1 | 2006 | 391 | 0.060 |
Why?
| Pregnancy | 1 | 2011 | 2614 | 0.060 |
Why?
| Polymerase Chain Reaction | 1 | 2005 | 533 | 0.060 |
Why?
| Blotting, Western | 2 | 2015 | 685 | 0.050 |
Why?
| Oncogenes | 1 | 2021 | 63 | 0.050 |
Why?
| Oxidative Stress | 1 | 2007 | 953 | 0.050 |
Why?
| Combined Modality Therapy | 2 | 2016 | 694 | 0.050 |
Why?
| Polycomb Repressive Complex 2 | 1 | 2021 | 50 | 0.050 |
Why?
| Cell Polarity | 1 | 2000 | 19 | 0.050 |
Why?
| Chromatin | 1 | 2021 | 155 | 0.050 |
Why?
| Cell Transplantation | 1 | 1999 | 4 | 0.050 |
Why?
| Mice, Inbred ICR | 1 | 1999 | 24 | 0.050 |
Why?
| Protein Disulfide-Isomerases | 1 | 2019 | 15 | 0.040 |
Why?
| Genes, Immunoglobulin Heavy Chain | 1 | 2019 | 14 | 0.040 |
Why?
| Histones | 1 | 2021 | 331 | 0.040 |
Why?
| Cell Membrane | 1 | 2000 | 279 | 0.040 |
Why?
| Radiation Chimera | 1 | 1998 | 5 | 0.040 |
Why?
| Osteoprotegerin | 3 | 2006 | 57 | 0.040 |
Why?
| Clone Cells | 1 | 1998 | 90 | 0.040 |
Why?
| Dose-Response Relationship, Drug | 2 | 2016 | 1478 | 0.040 |
Why?
| Radiography | 2 | 2012 | 519 | 0.040 |
Why?
| Multivariate Analysis | 2 | 2012 | 646 | 0.040 |
Why?
| In Situ Hybridization, Fluorescence | 1 | 2019 | 277 | 0.040 |
Why?
| Aged, 80 and over | 2 | 2017 | 3442 | 0.040 |
Why?
| DNA-Binding Proteins | 1 | 2021 | 463 | 0.040 |
Why?
| False Positive Reactions | 1 | 2017 | 68 | 0.040 |
Why?
| Tomography, X-Ray Computed | 2 | 2017 | 1210 | 0.040 |
Why?
| Indolizines | 1 | 2015 | 11 | 0.040 |
Why?
| Cyclic N-Oxides | 1 | 2015 | 15 | 0.040 |
Why?
| Imaging, Three-Dimensional | 1 | 2017 | 172 | 0.030 |
Why?
| S Phase | 1 | 2015 | 19 | 0.030 |
Why?
| Drug Synergism | 1 | 2015 | 171 | 0.030 |
Why?
| Genes, BRCA1 | 1 | 2015 | 24 | 0.030 |
Why?
| Transcriptome | 1 | 2018 | 347 | 0.030 |
Why?
| Follow-Up Studies | 2 | 2013 | 2384 | 0.030 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 210 | 0.030 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 318 | 0.030 |
Why?
| Predictive Value of Tests | 2 | 2007 | 1053 | 0.030 |
Why?
| Transcription, Genetic | 1 | 2015 | 419 | 0.030 |
Why?
| DNA Damage | 1 | 2015 | 358 | 0.030 |
Why?
| Transfection | 2 | 2004 | 410 | 0.030 |
Why?
| Interleukin Receptor Common gamma Subunit | 1 | 2012 | 10 | 0.030 |
Why?
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2012 | 11 | 0.030 |
Why?
| Interleukin-2 | 1 | 2012 | 75 | 0.030 |
Why?
| Mice, Inbred NOD | 1 | 2012 | 99 | 0.030 |
Why?
| Acute Disease | 1 | 2013 | 405 | 0.030 |
Why?
| Immunoenzyme Techniques | 1 | 2012 | 165 | 0.030 |
Why?
| Creatinine | 1 | 2012 | 170 | 0.030 |
Why?
| Glomerular Filtration Rate | 1 | 2012 | 138 | 0.030 |
Why?
| Lymphocyte Activation | 1 | 2012 | 197 | 0.030 |
Why?
| Receptors, Tumor Necrosis Factor | 2 | 2001 | 36 | 0.030 |
Why?
| C-Reactive Protein | 1 | 2012 | 159 | 0.020 |
Why?
| Receptors, Cytoplasmic and Nuclear | 2 | 2001 | 88 | 0.020 |
Why?
| Proportional Hazards Models | 1 | 2012 | 428 | 0.020 |
Why?
| Radiation-Sensitizing Agents | 1 | 2010 | 55 | 0.020 |
Why?
| Inhibitor of Apoptosis Proteins | 1 | 2009 | 21 | 0.020 |
Why?
| Antibody-Dependent Cell Cytotoxicity | 1 | 2009 | 15 | 0.020 |
Why?
| Incidence | 1 | 2013 | 1084 | 0.020 |
Why?
| Protein Transport | 1 | 2010 | 196 | 0.020 |
Why?
| Microtubule-Associated Proteins | 1 | 2009 | 78 | 0.020 |
Why?
| Peptides | 1 | 2010 | 278 | 0.020 |
Why?
| CDC2-CDC28 Kinases | 1 | 2008 | 15 | 0.020 |
Why?
| Down-Regulation | 1 | 2009 | 392 | 0.020 |
Why?
| Salvage Therapy | 1 | 2008 | 145 | 0.020 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2009 | 239 | 0.020 |
Why?
| Protein Binding | 1 | 2009 | 743 | 0.020 |
Why?
| Antineoplastic Agents, Hormonal | 1 | 2007 | 51 | 0.020 |
Why?
| Phospholipase C gamma | 1 | 2006 | 4 | 0.020 |
Why?
| Cytogenetic Analysis | 1 | 2007 | 89 | 0.020 |
Why?
| Caspase 9 | 1 | 2006 | 20 | 0.020 |
Why?
| Proteins | 1 | 2010 | 382 | 0.020 |
Why?
| Chi-Square Distribution | 1 | 2007 | 318 | 0.020 |
Why?
| Mitogen-Activated Protein Kinase 3 | 1 | 2006 | 56 | 0.020 |
Why?
| Retrospective Studies | 2 | 2012 | 6387 | 0.020 |
Why?
| Cyclin D | 1 | 2006 | 20 | 0.020 |
Why?
| Cell Cycle | 1 | 2008 | 274 | 0.020 |
Why?
| RNA, Neoplasm | 1 | 2006 | 55 | 0.020 |
Why?
| src-Family Kinases | 1 | 2006 | 54 | 0.020 |
Why?
| Bone Marrow Transplantation | 1 | 2007 | 149 | 0.020 |
Why?
| Cyclins | 1 | 2006 | 55 | 0.020 |
Why?
| Case-Control Studies | 1 | 2009 | 1242 | 0.020 |
Why?
| Chromosome Mapping | 1 | 2006 | 176 | 0.020 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2006 | 176 | 0.020 |
Why?
| Mice, Inbred BALB C | 1 | 2006 | 368 | 0.020 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2006 | 152 | 0.020 |
Why?
| Cluster Analysis | 1 | 2006 | 250 | 0.020 |
Why?
| Kaplan-Meier Estimate | 1 | 2007 | 514 | 0.020 |
Why?
| Data Interpretation, Statistical | 1 | 2006 | 177 | 0.020 |
Why?
| Transplantation, Autologous | 1 | 2007 | 476 | 0.020 |
Why?
| DNA, Complementary | 1 | 2004 | 147 | 0.020 |
Why?
| Logistic Models | 1 | 2007 | 991 | 0.020 |
Why?
| Young Adult | 1 | 2013 | 4320 | 0.010 |
Why?
| Recombinant Proteins | 1 | 2004 | 574 | 0.010 |
Why?
| Solubility | 1 | 2002 | 75 | 0.010 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2005 | 577 | 0.010 |
Why?
| Leukemia, Plasma Cell | 1 | 2002 | 34 | 0.010 |
Why?
| Acid Phosphatase | 1 | 2001 | 15 | 0.010 |
Why?
| Protein Structure, Tertiary | 1 | 2002 | 289 | 0.010 |
Why?
| Neoplasm Invasiveness | 1 | 2002 | 294 | 0.010 |
Why?
| Hodgkin Disease | 1 | 2001 | 50 | 0.010 |
Why?
| Adolescent | 1 | 2013 | 6890 | 0.010 |
Why?
| Isoenzymes | 1 | 2001 | 180 | 0.010 |
Why?
| LDL-Receptor Related Protein-Associated Protein | 1 | 2000 | 2 | 0.010 |
Why?
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2001 | 70 | 0.010 |
Why?
| Paraproteinemias | 1 | 2001 | 79 | 0.010 |
Why?
| Hepatocyte Growth Factor | 1 | 2000 | 14 | 0.010 |
Why?
| Reference Values | 1 | 2001 | 356 | 0.010 |
Why?
| Intercellular Adhesion Molecule-1 | 1 | 2000 | 75 | 0.010 |
Why?
| Epithelial Cells | 1 | 2000 | 256 | 0.010 |
Why?
|
|
Yaccoby's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|